Generation of novel immunotherapy and testing of blood cancer patients' cells
2016
Peking University Shenzhen Graduate School, Shenzhen, China(1)
South University of Science and Technology of China, Shenzhen, China(2)
South University of Science and Technology of China, Shenzhen, China(2)
CD38, as a cell surface antigen, is highly expressed in several hematologic malignancies and has been proven to be a good target for immunotherapy of the disease. In this study, the researchers aimed at targeting CD38 as an anti-cancer target by generating a series of nanobodies against CD38 with high affinities. To do this, they generated crystal structures of the complexes of CD38 and identified target epitopes. Chromobodies were generated to check CD38 expression in patients cells and results confirmed that CD38 was highly expressed in malignant MM cells compared with normal white blood cells. Further, the researchers generated an immunotoxin from the nanobodies which showed highly selective cytotoxicity against patient-derived MM cells as well as human cell lines. These results set the stage for the development of clinical therapeutics as well as diagnostic screening for myeloma.
Immuno-targeting the multifunctional CD38 using nanobody
Yong Juan Zhao(1), Hon Cheung Lee(1), Hongmin Zhang(2)
Added on: 07-28-2021
[1] https://www.nature.com/articles/srep27055[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
